Literature DB >> 10930681

Bovine viral diarrhea virus types 1 and 2 antibody response in calves receiving modified live virus or inactivated vaccines.

R W Fulton1, L J Burge.   

Abstract

Serums from calves receiving eight different commercial vaccines containing modified live virus (MLV) or inactivated bovine viral diarrhea virus (BVDV) immunogens were assayed for antibodies to types 1 and 2 BVDV strains. The immune response to the types 1 and 2 BVDV strains were evaluated in 48 calves receiving one of the eight vaccines for each group. For 7/8 vaccines, the BVDV vaccine immunogen was only type 1 whereas the remaining vaccine contained both types 1 and 2 immunogens. Calves administered MLV vaccine received only one dose at day 0, whereas those calves receiving the inactivated vaccines were administered two doses initially at days 0 and 28. Selected calves were revaccinated with only one dose at day 140. Animals vaccinated with type 1 vaccines developed titers to a broad range of type 1 BVDV, both cytopathic (CP) and noncytopathic (NCP) biotypes, with lower titers evident to type 2 BVDV strains. For some animals, the BVDV serum antibodies did not persist. Revaccination at day 140 induced a significant four-fold increase in animals with intermediate to low antibody titers. There did not appear to be any clear differences in antibody responses between type 1 MLV or inactivated vaccines. The calves receiving the inactivated vaccine containing types 1 and 2 had similar antibody levels to both types.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10930681     DOI: 10.1016/s0264-410x(00)00168-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Evaluation of bovine respiratory syncytial virus (BRSV) and bovine herpesvirus (BHV) specific antibody responses between heterologous and homologous prime-boost vaccinated western Canadian beef calves.

Authors:  Nathan E N Erickson; Adam Berenik; Herbert Lardner; Stacey Lacoste; John Campbell; Sheryl Gow; Cheryl Waldner; John Ellis
Journal:  Can Vet J       Date:  2021-01       Impact factor: 1.008

2.  Bovine viral diarrhea virus (BVDV) 1b: predominant BVDV subtype in calves with respiratory disease.

Authors:  Robert W Fulton; Julia F Ridpath; Jeremiah T Saliki; Robert E Briggs; Anthony W Confer; Lurinda J Burge; C W Purdy; Raymond W Loan; Glenn C Duff; Mark E Payton
Journal:  Can J Vet Res       Date:  2002-07       Impact factor: 1.310

3.  Comparison of humoral immune responses in dairy heifers vaccinated with 3 different commercial vaccines against bovine viral diarrhea virus and bovine herpesvirus-1.

Authors:  Luc DesCôteaux; Dominique Cécyre; Johanne Elsener; Guy Beauchamp
Journal:  Can Vet J       Date:  2003-10       Impact factor: 1.008

4.  Cellular targeting of engineered heterologous antigens is a determinant factor for bovine herpesvirus 4-based vaccine vector development.

Authors:  Gaetano Donofrio; Valentina Franceschi; Antonio Capocefalo; Simone Taddei; Chiara Sartori; Sabrina Bonomini; Sandro Cavirani; Clotilde S Cabassi; Cesidio F Flammini
Journal:  Clin Vaccine Immunol       Date:  2009-09-30

5.  Development of one-step SYBR Green real-time RT-PCR for quantifying bovine viral diarrhea virus type-1 and its comparison with conventional RT-PCR.

Authors:  Ni Zhang; Zhengwen Liu; Qunying Han; Jianming Qiu; Jinghong Chen; Guoyu Zhang; Zhu Li; Sai Lou; Na Li
Journal:  Virol J       Date:  2011-07-29       Impact factor: 4.099

6.  Host response to bovine viral diarrhea virus and interactions with infectious agents in the feedlot and breeding herd.

Authors:  Robert W Fulton
Journal:  Biologicals       Date:  2012-08-11       Impact factor: 1.856

7.  Fluorogenic RT-PCR assay (TaqMan) for detection and classification of bovine viral diarrhea virus.

Authors:  B Bhudevi; D Weinstock
Journal:  Vet Microbiol       Date:  2001-10-22       Impact factor: 3.293

8.  Response of calves persistently infected with noncytopathic bovine viral diarrhea virus (BVDV) subtype 1b after vaccination with heterologous BVDV strains in modified live virus vaccines and Mannheimia haemolytica bacterin-toxoid.

Authors:  Robert W Fulton; Douglas L Step; Julia F Ridpath; Jeremiah T Saliki; Anthony W Confer; Bill J Johnson; Robert E Briggs; R V Hawley; Lurinda J Burge; Mark E Payton
Journal:  Vaccine       Date:  2003-06-20       Impact factor: 3.641

Review 9.  Origination and consequences of bovine viral diarrhea virus diversity.

Authors:  Steven R Bolin; Daniel L Grooms
Journal:  Vet Clin North Am Food Anim Pract       Date:  2004-03       Impact factor: 3.357

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.